FDA workshop on 3-D printing planned; Dukal signs agreement with Champs;

@FierceMedDev: Water Street plans to grow a German specialty Dx company into a major player, through investment and M&A. ICYMI from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: It's official: Alere is spinning off its diagnostics biz. More | Follow @VarunSaxena2

@MichaelGFierce: From Harvard Research: Herpes-loaded stem cells used to kill brain tumors. More | Follow @MichaelGFierce

@EmilyWFierce: Gelesis brought in $12M for superabsorbent hydrogel technology that swells in the stomach to treat obesity. More from MedCityNews | Follow @EmilyWFierce

> FDA will hold a public workshop on 3-D printing on October 8 and 9. The Federal Register

> Dukal Corporation signed a 3-year agreement with Champs Group Purchasing to offer Champ's member with contract pricing on wound care patient products. Release

Biotech News

@FierceBiotech: Why did Pfizer's big fiesta for palbociclib fizzle? Story | Follow @FierceBiotech

@JohnCFierce: Elotuzumab: Bristol-Myers nabs another 'breakthrough' cancer drug title. More | Follow @JohnCFierce

@DamianFierce: From yesterday: The redacted bit of Pfizer's letter sort of spells out their passive-aggressive strategy. Image | Follow @DamianFierce

@EmilyMFierce: Scientists can have an impact on the antibiotic crisis by engaging the public and talking to media, says Ian Lipkin. | Follow @EmilyMFierce

> AstraZeneca slaps down Pfizer's 'final' $119B takeover bid. More

> Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data. Story

> Another animal health biotech plots an IPO. Item

Pharma News

@FiercePharma: Roche unveils more plans for plant expansions in Switzerland. Story | Follow @FiercePharma

@TracyStaton: If AstraZeneca were Harry Potter, would that make Pfizer Voldemort? More | Follow @TracyStaton

@EricPFierce: China forewarns drugmakers. It's not messing around when it comes to bribery as a sales tool. More | Follow @EricPFierce

@CarlyHFierce: First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline. News | Follow @CarlyHFierce

> How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? More

> Emboldened by their GSK probe, Chinese officials step up pharma snooping. Story

> Valeant's $47B Allergan buyout could spawn a breakup, CEO tells investors. News

CRO News

> WuXi wraps up construction on a new biologics shop. Item

> Bayer agrees to share trial data, but not without a list of caveats. Article

> PRA amps up its biologics footprint amid industry shift. Story

> Evotec's hybrid CRO approach pays off in Q1. More

> WuXi scores more double-digit growth amid its global expansion. Report

Biotech IT News

> Venter nabs AstraZeneca's R&D IT chief for Human Longevity. News

> Bayer, Boehringer extend access to clinical trial data. Item

> NIH lays out up to $20B in IT spending over coming decade. More

> HCL Tech adds Novartis to roster of Big Pharma clients. Story

> GSK signs up to access Metabolon's bioinformatics tools. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.